This article uses bare URLs, which are uninformative and vulnerable to link rot. Please consider converting them to full citations to ensure the article remains verifiable and maintains a consistent citation style. Several templates and tools are available to assist in formatting, such as reFill (documentation) and Citation bot (documentation). (August 2022) (Learn how and when to remove this message)

Taselisib
Clinical data

ATC code	None
Identifiers
IUPAC name 2-{4-[2-(1-Isopropyl-3-methyl-1H-1,2,4-triazol-5-yl)-5,6-dihydroimidazo[1,2-d][1,4]benzoxazepin-9-yl]-1H-pyrazol-1-yl}-2-methylpropanamide
CAS Number	1282512-48-4
PubChem CID	51001932
ChemSpider	29315044
UNII	L08J2O299M
KEGG	D11774
ChEMBL	ChEMBL2387080
CompTox Dashboard (EPA)	DTXSID00155842
Chemical and physical data
Formula	C₂₄H₂₈N₈O₂
Molar mass	460.542 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES CC1=NN(C(=N1)C2=CN3CCOC4=C(C3=N2)C=CC(=C4)C5=CN(N=C5)C(C)(C)C(=O)N)C(C)C
InChI InChI=1S/C24H28N8O2/c1-14(2)32-22(27-15(3)29-32)19-13-30-8-9-34-20-10-16(6-7-18(20)21(30)28-19)17-11-26-31(12-17)24(4,5)23(25)33/h6-7,10-14H,8-9H2,1-5H3,(H2,25,33) Key:BEUQXVWXFDOSAQ-UHFFFAOYSA-N

Taselisib (development code: GDC-0032) is a former cancer drug candidate that was in development by Roche. It is a small molecule phosphoinositide 3-kinase inhibitor targeting the PI3K isoform p110α (PIK3CA).^[1]^[2]

Roche announced in June 2018 that there would be no further development of taselislib following the top line results of the Phase III "Sandpiper" study.^[3] Currently running clinical trials^[4] were continued for patients exhibiting benefit.

References